Authors
Latest:
Applying ASCO GU 2024 Data to Clinical Practice in Bladder, RCC CarePaul V. Viscuse, MD, spotlights key data from the 2024 Genitourinary Cancers Symposium in bladder cancer and renal cell carcinoma.
Latest:
Dr. Simon on Ensuring Health Equity in Cancer CareMelissa A. Simon, MD, discusses ensuring health equity in cancer care.
Latest:
From Anguish to Action: Turning Despair Into Efforts to Improve Racial EquityOncology fellows at the University of North Carolina turned their despair over the murders of George Floyd and Breonna Taylor into an effort to improve racial equity.
Latest:
Dr Deng on the Evolution of the Hodgkin Lymphoma Treatment ParadigmChangchun Deng, MD, PhD, discusses the evolution of Hodgkin lymphoma management following data readouts at the 2023 ASH Annual Meeting.
Latest:
Dr. Bachanova on NK Cell Therapy in NHLVeronika Bachanova, MD, PhD, discusses findings from a spatial analysis of the tumor microenvironment in patients with non-Hodgkin lymphoma who received and responded to adoptive natural killer cell therapy.
Latest:
Dr Neparidze on the Implications of Early Data for Belantamab Mafodotin Plus Elotuzumab in R/R MyelomaNatalia Neparidze, MD, discusses clinical implications and future of belantamab mafodotin and elotuzumab in heavily pretreated, relapsed/refractory multiple myeloma.
Latest:
Dr Habib on Developments in Palliative Care For Patients With CancerM. Hamza Habib, MD, JD, MBA, FACP, FAAHPM, FRCPI, MRCP, discusses the development of novel technology-based strategies to improve palliative cancer for patients with cancer.
Latest:
Dr. Puri on Clinically Relevant Biomarkers in SCLCSonam Puri, MD, discusses recent research on clinically relevant biomarkers in small cell lung cancer.
Latest:
Dr Shen on Adjuvant CDK4/6 Inhibitors in HR+/HER2– Breast CancerSherry Shen, MD, discusses trials evaluating adjuvant CDK4/6 inhibitors in patients with early-stage, HR-positive, HER2-negative breast cancer.
Latest:
Incorporating Treatment Advances Into mRCC ManagementExpectations regarding the impact of research in metastatic renal cell carcinoma on the use of immunotherapy and targeted agents in routine clinical practice.
Latest:
Dr. Atkins on Safety Considerations For Neoadjuvant Approaches in Gastric CancerKatelyn M. Atkins, MD, PhD, discusses safety considerations for neoadjuvant approaches in patients with gastric cancer.
Latest:
Finding the Optimal Therapeutic Sequence for Advanced Hepatocellular CarcinomaSeveral breakthroughs in recent years have rapidly shifted the treatment landscape for advanced HCC.
Latest:
Emerging Strategies in the Management of Relapsed/Refractory CLLConsiderations for the future treatment landscape of relapsed/refractory CLL, in light of emerging practices and clinical trial data.
Latest:
Dr. Heimbach on the Need for Multidisciplinary Care in HCCJulie K. Heimbach, MD, discusses the need for multidisciplinary care in patients with hepatocellular carcinoma.
Latest:
Dr Sikov on the Use of CDK4/6 Inhibitors in the First-line Treatment of ER+/HER2- Breast CancerWilliam M. Sikov, MD, discusses the negative outcome seen with palbociclib in the phase 3 PALOMA-2 trial, and compares this to data on other CDK4/6 inhibitors in the first-line treatment of estrogen receptor–positive, HER2-negative breast cancers.
Latest:
Dr. Ozguroglu on the Individualization of Treatment in NSCLCMustafa Özguröğlu, MD, discusses the individualization of treatment in non-small cell lung cancer.
Latest:
Lung Cancer State of the Science Summit Recap | Chaired by: Isabel Preeshagul, DO, MBSIsabel Preeshagul, DO, MBS, and colleagues share updates from across the lung cancer space as discussed in a recent State of the Science Summit.
Latest:
Practice Pearls for Treatment of Secondary AML in the Community SettingPanelists discuss how treating secondary AML in the community setting requires a multifaceted approach, emphasizing early diagnosis, risk stratification, timely referral when necessary, and close collaboration with academic centers to provide optimal patient care.
Latest:
Dr. Evangelist on the Goals of the MYLUNG Consortium in Lung CancerMakenzi Evangelist, MD, discusses the goals of the MYLUNG Consortium in lung cancer.
Latest:
The Future of Metastatic and Unresectable Melanoma TreatmentThe panel concludes their discussion with a call for continued research and collaboration, emphasizing the need for more understanding of targeted therapies, monitoring tools like ctDNA, and ongoing development in the field of BRAF mutant melanoma treatment.
Latest:
Dr Cremolini on the Utility of xM and xM NeXT Personal Dx MRD AssaysChiara Cremolini, MD, PhD, discusses the use of the xM and NeXT Personal Dx assays in the detection of minimal residual disease in patients with cancer.
Latest:
Dr Maksimovic on a Novel Preclinical Model of Bone Metastasis in ccRCCStefan Maksimovic, MD, discusses the preclinical investigation of innovative tissue engineering with optical windows, state-of-the-art fluorescence reporter technology, and intravital multiphoton microscopy in mouse models with clear cell renal cell carcinoma.
Latest:
Dr. Kurtzberg on Long-term OS for Remestemcel-L in Pediatric Steroid-Refractory aGVHDJoanne Kurtzberg, MD, discusses the long-term survival outcomes from an observational cohort study evaluating remestemcel-L in pediatric patients with steroid-refractory acute graft-vs-host disease.
Latest:
Dr. Cheng on Advances With Immunotherapy-Based Combinations in OncologyJonathan D. Cheng, MD, discusses advances with immunotherapy-based combinations in oncology.
Latest:
Dr Kraft on VEGF Inhibitor–Induced Hypertension in RCCShawna Kraft, PharmD, BCOP, discusses the incidence and mitigation of VEGF inhibitor–induced hypertension in patients with renal cell carcinoma (RCC).
Latest:
American Oncology Network Celebrates Momentous Five-Year Anniversary of Closing the Cancer Care GapAmerican Oncology Network, one of the fastest-growing community oncology networks in the United States, proudly celebrated its fifth anniversary, commemorating a half-decade of excellence in advancing community oncology and driving value-based care initiatives to close the cancer care gap.
Latest:
Leveraging Immunotherapy in GI Malignancies: Looking to the FutureIn this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss next steps for research, including vaccination strategies, personalized cellular therapies, and more.
Latest:
Incorporating ctDNA Into Routine Practice: Clinical PearlsAdvice to GI oncologists in the community on using ctDNA testing to detect minimal residual disease and inform treatment decisions in colorectal cancer.
Latest:
The Importance of Lung Cancer Screening in Individuals Exposed to the World Trade Center DisasterInvestigators evaluated risk factor–based guidelines and risk model–based strategies for lung cancer screening in World Trade Center–exposed responders.
Latest:
UC Regents Approve UCSF Proton Therapy Center for Cancer CareUCSF Life Sciences Building will bring research, innovation, specialty care clinics, and world-class cancer therapy to San Francisco’s central waterfront.
.jpg?fit=crop&auto=format)
